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Oncogenic RAS proteins are commonly expressed in human cancer. 
To be functional, RAS proteins must undergo post-translational 
modification and localize to the plasma membrane (PM). Therefore, 
compounds that prevent RAS PM targeting have potential as putative RAS 
inhibitors. Here we examined the mechanism of action of oxanthroquinone 
G01 (G01), a recently described inhibitor of KRAS PM localization. We 
show that G01 mislocalized HRAS and KRAS from the PM with similar 
potency and disrupted the spatial organization of RAS proteins remaining 
on the PM. G01 also inhibited recycling of epidermal growth factor receptor 
and transferrin receptor, but did not impair internalization of cholera toxin, 
indicating suppression of recycling endosome function. In searching for 
the mechanism of impaired endosomal recycling we observed that G01 
also enhanced cellular sphingomyelin (SM) and ceramide levels and 
	 vi	
disrupted the localization of several lipid and cholesterol reporters, 
suggesting that the G01 molecular target may involve SM metabolism. 
Indeed, G01 exhibited potent synergy with other compounds that target 
SM metabolism in KRAS localization assays. 
When attached to a biotin moiety, G01 bound acylpeptide hydrolase 
(APEH) and blocked its enzymatic activity. Inhibition of APEH by 
ebelactone, an esterase inhibitor, or the knockdown of APEH mislocalized 
KRASG12V as well as phosphatidylserine from the PM. Together, these 
results suggest that G01 mislocalizes KRASG12V from the PM by binding 
to and inhibiting APEH function.  
Furthermore, G01 significantly abrogated RAS-RAF-MAPK signaling 
in MDCK cells expressing constitutively activated, oncogenic mutant 
RASG12V. G01 also inhibited the proliferation of RAS-less mouse 
embryonic fibroblasts (MEFs) expressing oncogenic mutant KRASG12V or 
KRASG12D but not RAS-less MEFs expressing oncogenic mutant 
BRAFV600E. Consistent with these effects, G01 inhibited the proliferation 
of KRAS-transformed pancreatic, colon, and endometrial cancer cells. 
Taken together, these results suggest that G01 should undergo further 
evaluation as a potential anti-RAS therapeutic. 
To enhance the potency of G01 for KRAS inhibition, we synthesized 
D01 and D02, two derivatives of G01 containing an additional geranyl or 
farnesyl group, respectively. D01 or D02 mislocalized KRAS more 
effectively than G01, and disrupted the clustering of KRAS at a much lower 
concentration than G01. As a consequence, D01 or D02 inhibited MAPK 
	 vii	
signaling downstream of oncogenic KRAS, as well as the proliferation of 
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Chapter 1 Introduction 
1.1 RAS biological function in normal and cancer cells 
RAS proteins are small GTPases that regulate cell growth, proliferation, and 
differentiation. RAS cycles between the inactive GDP-bound state and the active 
GTP-bound state in concert with the action of guanine nucleotide exchange factors 
(GEFs) and GTPase-activating proteins (GAPs). GEFs catalyze the hydrolysis of 
RAS-bound GDP and thus promote the binding of GTP, whose cellular 
concentration is much higher than that of GDP [1]. In contrast with GEFs, GAPs 
are responsible for the inactivation of RAS. Although RAS itself possesses 
GTPase activity, it is very ineffective at catalyzing the hydrolysis of GTP to GDP, 
which is performed >1000 fold more efficiently in presence of GAPs [1]. RAS GEFs 
and GAPs include many proteins. For instance, SOS, the most studied GEF, binds 
to GDP-bound RAS and activates it by facilitating GDP hydrolysis, or it can bind to 
GTP-bound RAS and further stimulate RAS activation [2]. SOS activation of RAS 
happens exclusively on the plasma membrane (PM), and is regulated by GRB2, 
which recruits SOS to PM-localized RAS [2]. 
Activated GTP-bound RAS regulate various biological functions by interacting 
with downstream effectors. Over eleven families of effectors have been identified 
so far, with some of them contributing to the malignant transformation of cancers. 
The first RAS effector to be identified in mammalian cells was the serine/threonine 
kinase RAF, which is also the best studied effector bound to RAS [3]. RAS-GTP 
binds to three different RAF proteins, CRAF, BRAF, and ARAF. When active, RAF 
proteins phosphorylate mitogen-activated protein kinase kinases MEK1 and MEK2, 
which consequently phosphorylate extracellular signal-regulated kinases ERK1 
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and ERK2. The phosphorylation of ERK1 and ERK2 activates a series of 
substrates in the cytosol and nucleus. For instance, ERK phosphorylates c-JUN, 
leading to the activation of the AP1 transcription factor and subsequent expression 
of many cell cycle regulators [4]. 
Another well studied RAS downstream effector is the type I 
phosphatidylinositol 3-kinase (PI3K). The catalytic domain of PI3K binds to RAS, 
which activates the lipid kinase activity of PI3K [5, 6]. PI3K catalyzes the 
phosphorylation of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) to 
phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3), a secondary 
messenger that binds to several downstream enzymes. The most studied of them 
is AKT, which mediates cell survival by preventing apoptosis [7, 8].  
Besides the RAS-RAF-MAPK and RAS-PI3K pathways, RAL represents 
another critical effector of RAS. The activation of RAL is dependent on the 
exchange factors RAL guanine nucleotide dissociation stimulator (RALGDS), 
RALGDS-like gene (RGL/RSB2), and RGL2/RLF. The activation of RAL switches 
on phospholipase D1 and CDC42/RAC-GAP-RAL binding protein 1 (RALBP1), 
which act along with AKT to mediate cell cycle arrest and apoptosis [9]. 
Phospholipase Cε is another important component of the RAS signaling 
pathway. It hydrolyzes PtdIns(4,5)P2 to diacylglycerol and inositol-1,4,5- 
trisphosphate (Ins(1,4,5)P3) [10], and is responsible for protein kinase C (PKC) 
activation and calcium mobilization. 
A recent unpublished study by Mark R. Philips lab has identified hexokinase 
1 (HK1) as a novel effector of RAS. This is the first evidence of RAS directly 
modulating a metabolic enzyme.  
The proper function of RAS is crucial for normal cells, with RAS mutations 
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instead leading to abnormal development and cancer. RAS was identified initially 
in oncogenic viruses and was characterized as a 21-kDa protein (p21) [11]. These 
viruses cause sarcomas both in vivo and in vitro. In 1982, mutated RAS was 
discovered in human cancer [12]. Since then, over 500 cancer genes have been 
identified and validated, however RAS remains the most mutated oncogene [13] 
and is present in such form in approximately 15% of all human cancers. The most 
abundant mutation sites are on codons 12, 13, and 61; they block GDP hydrolysis 
and lock RAS in the GTP-bound active state, leading to constitutive activation of 
downstream effectors [13-15]. RAS proteins include three isoforms, KRAS, HRAS, 
and NRAS, which are encoded by separate genes. They contain an almost 
identical G-domain but very different hypervariable regions (HVRs), which 
determine the non-redundant biological function of each isoform. Among all RAS 
isoforms, KRAS is most frequently mutated in human cancers and, therefore, is 
the most clinically relevant [16, 17]. 
 
1.2 Post-translational modification of RAS 
To allow them to function, RAS proteins must localize to the inner leaflet of 
the PM [18]. To localize to the PM, the C-terminus of RAS must be processed 
correctly after the protein’s synthesis. Different RAS isoforms have different C-
termini, which implies varying post-translational modifications. A CAAX (where C 
= cysteine, A = aliphatic amino acid, and X = serine or methionine) motif exists in 
every RAS isoform. The cysteine of the CAAX motif in all RAS isoforms is 
prenylated by farnesyltransferase [19]. Then, the AAX of the CAAX motif is cleaved 
by RAS-converting enzyme 1 (RCE1), and a C-terminal cysteine farnesyl carboxy-
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methyl ester is generated by isoprenylcysteine carboxyl methyltransferase (ICMT) 
[20]. In addition to the farnesyl moiety on the C-terminal cysteine, a second signal, 
which varies among different RAS isoforms, is required to further stabilize the 
interaction with the PM. KRAS4B (hereafter referred to as KRAS) contains a 
positively charged polylysine domain that interacts with the negatively charged 
phosphatidylserine (PtdSer) on the PM [21]. HRAS and NRAS contain one or two 
palmitoyl moieties for interaction with the PM [19, 22] and, in the case of NRAS, 
other hydrophobic residues upstream of the HVR also contribute to the PM 
interaction [22]. Finally, a minor splice variant of KRAS, KRAS4A, contains both 
the polylysine domain as well as a palmitoyl moiety for PM interaction [22].  
 
1.3 RAS nanoscale organization on the PM and lipid dependence  
RAS interact with PM lipids to form nanoclusters on the PM. About 40% of 
RAS proteins exist as immobile nanoclusters, whereas the rest are mobile on the 
PM [23, 24]. The diameter of RAS nanoclusters is about 9 nm and they include 6–
7 RAS proteins per cluster. The clusters are constantly assembling and 
disassembling with a lifetime of 0.1–1 s [24, 25]. Recent studies have reported that 
the formation of RAS nanoclusters depends on an intermediate RAS dimer [26-
30].  
Different RAS isoforms assemble into distinct GTP or GDP nanoclusters. As 
a result, even if they share a conserved G-domain, different RAS isoforms have 
different biological functions [31]. The structure of the minimal membrane anchor 
of each isoform determines the localization and spatial segregation of their cognate 
isoforms on the PM [23]. Additionally, changes in the G-domain conformational 
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orientation upon GTP loading contribute to the GTP-dependent spatial segregation 
of RAS. Indeed, this plasticity explains why RAS form different clusters with GTP 
or GDP loading [32, 33].  
These non-overlapping nanoclusters are defined by a distinct lipid 
composition. First, different RAS isoforms exhibit a different dependency on 
cholesterol. HRAS-GDP forms cholesterol-dependent nanoclusters. After GTP 
binding, HRAS forms cholesterol-independent clusters [23]. NRAS, in contrast, 
forms cholesterol-dependent nanoclusters when it binds GTP but cholesterol-
independent nanoclusters when it binds GDP [23]. Finally, KRAS forms 
cholesterol-independent nanoclusters, irrespective of whether it is loaded with 
GTP or GDP [23, 24]. Besides cholesterol, anionic lipids also play very important 
roles in RAS PM binding and clustering. Recently, different RAS isoforms have 
been reported to associate with different groups of anionic phospholipids [34]. For 
example, PtdSer is required by KRAS nanoclusters, but not HRAS nanoclusters, 
and is important for the regulation of KRAS biological functions [34].  
 
1.4 PtdSer-dependent lateral segregation of RAS and its 
implications for drug discovery 
Nanocluster formation of RAS is critical for downstream signal transmission. 
When active, the nanoclusters of different RAS isoforms interact with a defined set 
of phospholipids, leading to isoform-specific downstream signaling [35, 36]. 
Changing the lipid content on the PM abolishes the spatial segregation of RAS and 
blocks the corresponding biological functions [31]. For instance, overexpression of 
GFP-HRASG12V disrupts KRAS nanoclustering and inhibits its function, by 
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altering the distribution of PtdSer on the PM [34]. Disruption of KRAS 
nanoclustering by HRASG12V selectively targets cancer cells that express 
oncogenic KRAS [34]. This effect is lipid-regulated and G-domain-independent, as 
indicated by the fact that overexpression of the C-terminal HVR of HRAS without 
the G-domain had the same effect on KRAS nanoclustering [34].  
Given the abundance of PtdSer on the PM, HRAS overexpression can hardly 
affect the nanoclustering of KRAS, if all PtdSer participates in KRAS clustering. 
Indeed, only ~40% of PtdSer molecules are mobile when RAS nanoclusters are 
being formed [25, 34, 37], and only a fraction of them actually participate in RAS 
nanocluster formation [34]. Overexpressed HRAS competes with KRAS for a 
limited PtdSer pool, which explains the HRAS-induced disruption of KRAS 
nanoclustering [34].  
This phenomenon of spatial cross-talk has great significance for the 
development of anti-RAS pharmacological agents, because the latter can be used 
to modulate lipid pools and thus control RAS signaling. For example, nonsteroidal 
anti-inflammatory drugs (NSAIDs) disrupt HRAS and KRAS nanoclusters by 
stabilizing cholesterol domains. As a result, CRAF activation induced by oncogenic 
HRAS or KRAS is abolished by NSAIDs [38]. Another example includes 
pharmacological agents that disrupt sphingomyelin (SM) metabolism. They alter 
nanoclustering formation and PM interaction of RAS by disrupting PtdSer and 
cholesterol content on the PM, causing inhibition of RAS function (also discussed 
in Chapter 1.8) [39-41]. A recent unpublished study by Dharini van der Hoeven 
showed that the disruption of PM cholesterol by pharmacological agents that 
altered SM metabolism impaired the membrane localization of epidermal growth 
factor receptor (EGFR), and inhibited the proliferation of oral cancer cells 
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overexpressing EGFR.  
 
1.5 Endosomal trafficking of RAS 
RAS proteins are localized predominantly on the PM; however, a series of 
organelles are also targeted by RAS. Among these, the endosome is the most 
interesting one for its critical role in regulating RAS signaling and function [35].  
All RAS isoforms are trafficked through the endosomal system for turnover on 
the PM. The endosomal trafficking of HRAS and NRAS relies mainly on a cycle of 
acylation and deacylation. HRAS and NRAS are depalmitoylated by a thioesterase 
and released into the cytosol due to reduced hydrophobicity. The depalmitoylated 
HRAS and NRAS are transported to the Golgi complex for a new round of 
palmitoylation. The repalmitoylated HRAS and NRAS are then trafficked to the PM 
via membrane carriers that likely involve the recycling endosome (RE) [42-46]. A 
recent study has shown that vacuolar protein sorting-associated protein 35 
(VPS35), a component of the retromer complex, facilitates NRAS recycling from 
endosomes to the Golgi complex [47]. In addition to post-Golgi trafficking, HRAS 
and NRAS can be endocytosed in a clathrin-dependent manner [48]. Moreover, 
ubiquitinylation facilitates the endocytosis and sorting of these two RAS isoforms 
[49]. 
Compared to HRAS and NRAS, KRAS interacts more weakly with the PM, 
because interaction between the polybasic domain and the PM is not as strong as 
that between the palmitoyl group and the PM. Given the weaker interaction, KRAS 
dissociates more easily from the PM [50, 51]. The endocytosed KRAS dissociates 
from the vesicles and is released into the cytosol, where it diffuses freely until it 
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associates with another membrane. Due to the extent of endomembranes, KRAS 
ends up binding to all cellular membranes before it is trafficked back to the PM [51]. 
Prior to reaching again the PM, KRAS needs to diffuse back into the cytosol. 
The diffusion is facilitated by a cytosolic solubilization factor, PDEd, which captures 
KRAS in the cytosol [51]. PDEd is essential for the trafficking of KRAS to the PM, 
but it is not sufficient. The ARF-like GTPase ARL2 is required for the release of 
KRAS from PDEd following binding to the allosteric site and a change in the 
conformation of PDEd [51]. Because ARL2-GTP is concentrated in the perinuclear 
area, KRAS is released mostly in this region, where it can easily interact with 
RAB11-positive RE vesicles enriched with negatively-charged PtdSer. Finally, 
KRAS is trafficked back to the PM via the RE [51].  
 
1.6 Blocking RAS PM localization inhibits RAS function 
Blocking RAS PM localization abrogates RAS biological function, as effector 
activation occurs exclusively on the PM [18]. So far, most studies have focused on 
pharmacological agents responsible for disrupting the post-translational 
modification of RAS. 
Farnesyltransferase inhibitors (FTIs) prevent HRAS from interacting with the 
PM by hindering the attachment of farnesyl to the CAAX cysteine. Two FTIs, 
lonafarnib and tipifarnib, have been shown to be effective against HRAS-driven 
tumors in mouse studies and clinical trials [52]. However, KRAS and NRAS can 
become geranylgeranylated and remain fully functional during FTI treatment [53, 
54]. Therefore, FTIs are only applicable to mutant HRAS therapy, which is rare 
among cancers with mutated RAS. 
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Another group of inhibitors of RAS post-translational modifications includes 
RCE1 and ICMT inhibitors [55-59]. However, these two enzymes are critical for the 
regulation of many other cellular functions and, therefore, inhibitors of these two 
enzymes are toxic to normal patient tissues. In the case of HRAS and NRAS, 
inhibitors of palmitoylation have also been considered as putative anti-RAS 
therapeutics [43]. However, the application of these inhibitors has been limited 
because the majority of RAS-dependent cancers contains mutant KRAS.  
Other post-translational modifications of RAS that determine its localization 
on the PM have also been proposed as therapeutic targets. PKC alpha (PKCα) or 
protein kinase G (PKG) activation induces the intracellular redistribution of KRAS, 
because both kinases phosphorylate KRAS on S181 [60, 61]. The negatively 
charged phosphoryl group neutralizes the electrostatic interaction between the 
polybasic domain and PtdSer. Therefore, phosphorylated S181 prevents KRAS 
from binding to the anionic lipids on the RE [61]. Based on this phenomenon, 
bryostatin, a PKCα agonist, has been reported to effectively inhibit RAS PM 
localization and function in mouse xenograft models [60]. Recent studies have 
shown that activation of PKG through the 5' AMP-activated protein kinase (AMPK)-
endothelial NOS (eNOS)-cGMP secondary messenger pathway blocks RE-
mediated KRAS recycling [61]. Hence, mitochondrial inhibitors that induce the 
AMPK-eNOS-cGMP secondary messenger pathway have additional potential as 
anti-RAS therapeutics [61].  
Finally, blocking the function of key proteins in the endosomal trafficking of 
RAS also inhibits its interaction with the PM. Knockdown or inhibition of PDEδ 
prevents PM enrichment of KRAS [51, 62]. Knockdown of RAB11, a critical small 
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GTPase regulating RE function, or expression of dominantly negative RAB11 also 
disrupts the cellular localization of KRAS [51].  
 
1.7 Other strategies for RAS inhibition 
Besides inhibition of RAS PM localization, other approaches aimed at 
inhibiting the biological function of RAS have been explored. These approaches 
include direct inhibition of RAS, inhibition of RAS effectors, identification of protein 
targets that have synthetic lethal interactions with RAS, and targeting RAS-driven 
metabolic changes [13]. 
 
1.7.1 Direct inhibition of oncogenic RAS function 
Wild-type RAS proteins require the cycling between inactive and active forms 
to function normally, whereas mutated RAS are locked in the GTP-bound state. 
Therefore, efforts have been made to find GTP-competitive inhibitors. However, 
this attempt has failed because GTP binds RAS with picomolar affinity. In addition, 
no molecules that could function as GAPs for mutant RAS have been found either 
[63].  
Several binding pockets of RAS have been identified using computational 
approaches. A number of inhibitors that bind these pockets have the ability to 
inhibit the formation of RAS-RAF complexes. For instance, sulindac analogs bind 
to the RAF-binding domain of RAS and thus prevent formation of the RAS-RAF 
complex [64, 65]. Sulindac inhibits mitogen-activated protein kinase (MAPK) 
signaling as well as the proliferation of RAS-transformed cancer cells [66]. 
However, these analogs are not potent enough for clinical use.  
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In addition to inhibitors of the RAS-RAF complex, some RAS-binding chemical 
compounds disrupt RAS-GEF binding. Among these compounds, the most 
promising is a peptide (HBS3) that is based on the structure of the alpha helix of 
SOS1. HBS3 binds to RAS in the cleft near the SI and SII regions, effectively 
inhibiting binding of SOS1 to RAS. MAPK signaling downstream of RAS is inhibited 
by this peptide whose dissociation constant (Kd) is 158 µM [67].  
Recent studies have identified several compounds that bind specifically to 
certain mutant forms of RAS. For instance, an inhibitor that binds specifically to 
KRASG12C was identified for treating non-small-cell lung cancer as KRASG12C 
is the most frequent RAS mutation in this type of cancer. By targeting selectively 
KRASG12C-expressing cancer cells the inhibitor interferes with SOS1-regulated 
nucleotide exchange as well as RAS-RAF complex formation [68].  
 
1.7.2 Inhibition of RAS effectors 
Inhibition of RAS downstream effectors has been the most successful 
approach so far for blocking RAS signaling. The most well characterized inhibitors 
have targeted RAF-MEK-ERK signaling.  
The RAF-MEK-ERK signaling pathway was initially thought to be simple and 
unidirectional. However, it turns out that the RAF-MEK-ERK cascade is regulated 
by several inputs and outputs, feed-forward and feedback mechanisms [69], which 
has complicated the development of inhibitors targeting this pathway.  
Four RAF inhibitors have been approved by the US Food and Drug 
Administration (FDA). One of these inhibitors, sorafenib, not only inhibits RAF 
function, but also blocks members of the vascular endothelial growth factor 
receptor (VEGFR) family [70, 71] and thus VEGFR-mediated tumor angiogenesis. 
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Two other FDA-approved ATP-competitive RAF inhibitors are vemurafenib and 
dabrafenib, which paradoxically activated ERK signaling when tested in RAS-
mutant cancers [72-75]. Furthermore, these inhibitors promote RAF dimerization, 
which activates RAF function [76, 77]. Current efforts are focusing on a new 
generation of RAF inhibitors that do not enhance RAF dimerization.  
More than a dozen MEK inhibitors have also been evaluated clinically. One 
of these, trametinib, has been approved by the FDA for treatment of metastatic 
melanoma harboring a BRAF mutation. One of the advantages of MEK inhibitors 
is that they are highly selective. However, sometimes the inhibitors are not 
effective because they block ERK feedback inactivation of RAF. In addition, RAS-
mutant cancers are sometimes characterized by an increased activation of 
receptor tyrosine kinases (RTKs) upstream of RAS. Activated RTKs can enhance 
ERK activity to a level that is above the suppression threshold. As a consequence, 
therapeutic responses are not observed due to overactivation of RTKs [78].  
Several ERK inhibitors are also under evaluation. The inhibition of ERK, 
however, blocks ERK feedback inactivation of RAF the same way as MEK 
inhibitors do, which prolongs MEK activation. Furthermore, a recent study shows 
that protective autophagy, which is a cellular process of self-consumption, can be 
induced by inhibition of the RAS-RAF-MAPK pathway. This process helps the cells 
avoid the harm caused by inhibitors of the RAS-RAF-MAPK pathway [79]. 
Therefore, a combination of inhibitors of different protein targets in various 
pathways may be tested in the future for more effective RAS inhibition in human 
cancers. 
 
1.7.3 Identification of synthetic lethal interactions 
	
	13	
There are two types of synthetic lethal interactions. The first type of potential 
synthetic lethal targets includes pathways that are responsible for relieving stress 
induced by oncogenes. For instance, in oncogenic KRAS-dependent cancers, 
cells produce more proteins than normal cancer cells. These cells with mutated 
KRAS are therefore under proteotoxic stress, and proteasomes are critical for 
relieving this condition. When such KRAS-dependent cancer cells are treated with 
proteasome inhibitors, they become vulnerable to proteotoxicity, whereas cancer 
cells with wild-type KRAS are less responsive to proteasome inhibitors [80-82].  
Another type of synthetic lethal targets includes proteins in pathways that are 
required to compensate for changes caused by oncogenic pathways. For instance, 
in BRCA1- and BRCA2-mutant breast cancer cells, DNA homologous 
recombination repair is damaged by BRCA1 and BRCA2 mutations. As a result, 
poly(ADP-ribose) polymerase (PARP) becomes indispensable for these cells 
because PARP regulates non-homologous end-joining DNA repair. Therefore, 
PARP inhibitors show a potent effect on inhibition of BRCA-mutant breast cancer 
[13].  
 
1.7.4 Targeting RAS-driven metabolic changes 
Metabolic changes and adaptations represent a hallmark of cancer. RAS-
driven metabolic changes are critical for the development of cancers, their 
maintenance and their growth. Therefore, targeting these metabolic pathways 
represents a possible therapeutic approach against cancers that are dependent 
on oncogenic RAS.  
The first such strategy is to target metabolic recycling processes. In cancers 
driven by oncogenic RAS, autophagy and macropinocytosis are required for the 
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maintenance of cancer cells, because aggressive cancers require vast amounts of 
energy for growth and metastasis. Autophagy and macropinocytosis satisfy the 
energy requirement of RAS-dependent cancer cells. Therefore, inhibitors of these 
two biological processes have been tested as tumor suppressors. At present, 
autophagy inhibitors, such as chloroquine and its derivative hydroxychloroquine 
(HCQ), are being tested in clinical trials involving several types of cancers, 
including pancreatic cancers with KRAS mutations [83, 84]. Recent studies have 
revealed that ERK inhibition increases the dependence of pancreatic cancer cells 
on autophagy, suggesting the important role of autophagy in the RAS signaling 
pathway [85]. Furthermore, because both autophagy and macropinocytosis 
require normal lysosome function, lysosome inhibitors are also potential 
pharmacological agents that inhibit metabolic recycling in RAS-dependent cancers.  
The second strategy is to target metabolic changes, such as glucose 
metabolism. Mutant KRAS enhances glucose metabolism in cancer cells by 
altering the rate-limiting enzymes. As a result, more glycosylation and ribose 
precursors required for DNA and RNA synthesis are produced, thus sustaining the 
aggressive proliferation of cancer cells. Knockdown of these rate-limiting enzymes 
has been shown to effectively inhibit KRAS-dependent pancreatic cancer cells in 
vivo and in vitro [86]. 
 
1.8 SM metabolism is crucial for cancer cell survival as well as 
RAS function 
Sphingolipids are components of the cell membrane and regulate a number 
of biological functions, such as cell growth, proliferation, and migration [87]. In 
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cancer cells, SM metabolism plays key roles in regulating cell death. First, 
ceramide induces apoptosis in cancer cells, possibly by facilitating mitochondrial 
outer membrane permeabilization (MOMP), an initiation step in mitochondria-
induced apoptosis [88]. In this process, ceramide is responsible for forming 
channels on the planar phospholipid membranes and outer membranes of 
mitochondria that allow the passage of proteins released by MOMP from 
mitochondria to the cytosol for cell apoptosis [88]. Second, ceramide induces 
tumor cell necroptosis by interacting with the phosphatase 2A inhibitor I2PP2A and 
activating the tumor suppressor serine/threonine-protein phosphatase 2A (PP2A) 
[89, 90]. Finally, ceramide induces autophagy by targeting autophagosomes to 
mitochondria, whereas accumulation of SM in cells hinders the maturation of 
autophagosomal membranes [91, 92]. These observations suggest that different 
sphingolipids play different roles in autophagy. 
While ceramide induces cancer cell death, sometimes cancer cells find ways 
to evade this effect. The most outstanding example is the 
sphingosine-1-phosphate (S1P)-induced anti-apoptotic effect [91, 92]. When 
cancer cells are under stress such as chemotherapy, ceramide and sphingosine 
are generated to manage cell death. However, the conversion of ceramide to S1P 
makes cancer cells escape death, leading to S1P-dependent cancer cell survival. 
Therefore, therapeutic strategies have been developed to target pro-survival S1P-
S1P receptor signaling [93]. 
SM metabolism has been reported in recent years as a regulator of KRAS PM 
localization and function. We have described several classes of chemical 
compounds that inhibit oncogenic KRAS PM localization and function by disrupting 
SM metabolism. The most outstanding compounds include fendiline and 
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staurosporine (STS).  
Fendiline is a clinically obsolete FDA-approved calcium channel blocker [94]. 
However, fendiline mislocalizes oncogenic KRAS from the PM through a 
mechanism unrelated to calcium channel blocking [41], which involves instead 
inhibition of acid sphingomyelinase (ASM) [39, 40]. ASM is responsible for 
catalyzing the breakdown of SM. Inhibition of ASM by fendiline causes SM 
accumulation in the lysosomal compartment, which in turn reduces the amount of 
PtdSer and cholesterol on the PM [39, 40]. As a result of the loss of PtdSer from 
the PM, PM localization of KRAS is blocked and its spatial organization on the PM 
is disrupted.  
STS was previously reported as a PKC inhibitor. However, KRAS 
mislocalization by STS is not related to PKC [95]. We believe that STS mislocalizes 
KRAS by disrupting SM metabolism. STS decreases the cellular level of ORMDL, 
a protein that negatively regulates serine-palmitoyltransferase (SPT) [96]. 
Because SPT catalyzes the synthesis of ceramide, the precursor of SM, STS 
enhances the cellular level of SM [96]. Increased SM causes mislocalization of 
PtdSer and cholesterol from the PM, thus critically affecting oncogenic KRAS and 
HRAS PM binding and clustering [96].  
A recent study on a series of ASM inhibitors has reported that imipramine, 
desipramine, and amitriptyline lead to the same mislocalization of KRAS as 
fendiline [39]. These FDA-approved antidepressants can be potentially employed 
as anti-RAS pharmacological agents. In addition, we have shown that knocking 
down several key enzymes in SM synthesis and turnover pathways blocks KRAS 
PM localization and function to a varying extent [39]. Therefore, pharmacological 





























Chapter 2 Methods and Materials 
This chapter is  based upon: Tan L, Cho KJ, Neupane P, Capon RJ, Hancock 
JF: An oxanthroquinone derivative that disrupts RAS plasma membrane 
localization inhibits cancer cell growth. J Biol Chem. 2018 Aug 31;293(35):13696-
13706. The journal does not require permission to reuse publications of the authors 
for dissertation. 
2.1 Materials 
Oxanthroquinone deratives were synthesized as described previously [97] by 
Robert J. Capon (University of Queensland) and dissolved in dimethyl sulfoxide 
(DMSO). Cell culture media and fetal bovine serum (FBS) were purchased from 
HyClone unless described otherwisely. Rabbit anti-acylpeptide hydrolase (APEH) 
antibody (PA5-11354) was purchased from Thermo Fisher Scientific. Rabbit anti-
RAB11 (3539), Rabbit anti-phospho-p44/42 mitogen-activated protein kinase 
(MAPK) (ppERK1/2) (Thr202/Tyr204) (9101), rabbit anti-ERK (4695) antibodies 
were purchased from Cell Signaling Technology (Beverly, MA). Mouse anti-β-actin 
(A1978) antibody was purchased from Sigma Aldrich. Rabbit anti-mGFP antibody 
for immunogold labeling was generated in house. Transferrin from human serum, 
Alexa FluorTM 555 Conjugate (T35352), Cholera Toxin Subunit B (Recombinant), 
Alexa FluorTM 647 Conjugate (C34778), and Wheat Germ Agglutinin, Alexa FlourTM 
488 Conjugate (W11261) were purchased from Thermo Fisher Scientific.  
 
2.2 Cell culture 
BxPC3, MiaPaCa-2, MOH were provided by Craig Logsdon, KLE, Hec-1a 
cells by Karen Lu, Hec-1b cells by Bryan Hennessey, and Hec-50 cells by Russell 
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Broaddus, all at MD Anderson Cancer Center, Houston, TX. Other cell lines were 
purchased from the American Type Culture Collection (ATCC) or provided by the 
NCI Ras Initiative. The Madin-Darby canine kidney (MDCK), A431 cell line and 
RAS-less mouse embryonic fibroblasts (MEFs) were maintained in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 2mM L-glutamine and 10% 
FBS. Chinese hamster ovary (CHO) cells were maintained in Ham’s F-12K 
medium (ATCC) supplemented with 10% FBS 2mM L-glutamine. BxPC3, MOH, 
NCI-1975, NCI-23, NCI-2122, NCI-441, NCI-H508 cells were grown in RPMI-1640 
supplemented with 10% FBS. MiaPaCa-2 cells were grown in DMEM 
supplemented with 10% FBS and 2.5% horse serum. KLE and Hec-50 cells were 
maintained in DMEM-F-12 medium supplemented with 10% FBS. Hec-1a and 
Hec-1b cells were grown in McCoy’s 5a medium supplemented with 10% FBS. SK-
CO-1 cells were maintained in Eagle’s MEM supplemented with 10% FBS. CaCO-
2 cells were grown in Eagle’s MEM supplemented with 20% FBS. SW948 cells 
were grown in Leibovitz’s L15 medium with 10% FBS. TLA293t cells were 
maintained in DMEM supplemented with 10% FBS.  
 
2.3 Transfection and selection of monoclonal stable cell lines 
Cells were seeded and reached 90% confluency before transfection. Cells 
were then treated with Opti-MEM reduced serum medium containing 4 μg plasmid 
DNA and 10 μl Lipofectamine 2000 (11668019, Thermo Fisher Scientific) for 24 h. 
The cells were selected in cell growth medium with antibiotics for 7 days. Only one 
single cell was seeded onto each well in several 96-well plates. Cell were 
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maintained and observed under a fluorescence microscope. The cell colonies with 
homogeneous fluorescence-tagged proteins were selected and further cultured.  
 
2.4 Lentiviral infection 
2.4.1 Lentivirus production in TLA293t cells 
TLA293t cells were seeded onto 6-well plates and reached 70% confluency 
before transfection. The lentiviral DNA plasmid mix was transfected into cells as 
described in 2.3. TLA293t cells were cultured in Opti-MEM reduced serum medium 
for 24 h and then growth medium for 40 h. The growth medium was collected by 
centrifuge at 3000 rpm for 15 min. The concentration of virus was determined. 
2.4.2 Lentiviral infection 
Cells were seeded on 6-well plates and reached 90% confluency before 
infection. The virus media were added to cells with 8ug/ml polybrene. Fresh media 
with antibiotics were added to the cells 24 h later. The cells were selected with 
5ug/ml puromycin for 5 days. If necessary, monoclonal stable cell lines were 
selected as described in 2.2. 
 
2.5 Fluorescence microscopy 
Cells were grown on coverslips and fixed with 4% paraformaldehyde (PFA). 
The coverslips were mounted in mowiol and imaged in a confocal microscope 
(Nikon A1R) using a 60X or 100X objective. The manders coefficient plugin from 
ImageJ was used for quantification. 
 
2.6 Electron microscopy 
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MDCK cells expressing mGFP tagged protein were seeded on fibronectin 
coated, gold electron microscopy (EM) grids (IGG200, Ted Pella Inc). Cells were 
grown on the grids for 48 h. Apical PM was removed by placing a Whatman filter 
paper soaked in PBS onto the cells for 5 min, applying brief pressure and then 
removing the PBS-soaked filter paper. The cytosolic surface of the adherent basal 
PM was exposed because the apical PM was removed. The cytosolic leaflet of the 
basal PM was washed, fixed with PFA and glutaraldehyde, and labeled with anti-
GFP antibody conjugated to 4.5-nm gold particles. Digital images of intact 
immunogold-labeled PM sheets were obtained via a JEOL 1400 transmission EM 
at 100,000x magnification. Intact 1 µm2 areas of the PM sheet were identified and 
the (x,y) coordinates of the gold particles were determined using ImageJ. 
Univariate K-functions [98] were calculated as described previously and 
standardized on the 99% confidence interval (CI) [23, 99, 100]. Bootstrap tests to 
examine differences between replicated point patterns were constructed as 
described previously, and statistical significance evaluated against 1000 bootstrap 
samples [24, 100]. 
 
2.7 Western blotting 
Cells were washed in ice-cold phosphate-buffered saline (PBS) and lysed for 
10 min on ice in buffer containing 50 mM TrisCl (pH 7.5), 75 mM NaCl, 25 mM NaF, 
5 mM MgCl2, 5 mM EGTA, 1 mM dithiothreitol, 100 μM Na3VO4, 1% NP40, and 
protease inhibitors. The resulting whole cell lysate was centrifuged at 14,000 rpm 
for 20 min to remove cell debris and 20μg of the supernatant analyzed by SDS-
PAGE. After SDS-PAGE, proteins were transferred to PVDF membranes using 
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semidry Western transfer. After incubation with primary and secondary antibodies 
the protein of interest was visualized using enhanced chemiluminescence 
(SuperSignal; Pierce) with ChemiDoc MP System (Bio-rad) and quantified with 
ImageJ.  
 
2.8 Cell proliferation assay 
Tumor cells or RAS-less MEFs were seeded in 24-well plates. After 24 h, cells 
were treated with vehicle (DMSO) or 5 μM G01 for 72 h. The cells were trypsinized 
and counted. The cell number of G01-treated cells was normalized to that of the 
DMSO-treated cells.  
 
2.9 Lysenin staining 
Maltose binding protein (MBP)-GFP-Lysenin fragment (amino acid residues 
161 to 297) was purified as described previously [39, 40]. For lysenin staining, 
MDCK cells were fixed with 4% PFA, permeabilized or not permeabilized with 0.05% 
saponin, and then incubated with 60 μg/ml MBP-GFP-lysenin for 15 min. 
 
2.10 Pull-down assay  
2.10.1 Determining relative RAB11-GTP level with GST-FIP3 
GST tagged FIP3 fragment (Kindly provided by Emilio Hirsch, Italy) was 
produced as previously described [101]. Cells with or without drug treatment were 
lysed and incubated with GST-FIP3 for protein binding. Glutathione agarose beads 
were added to cells lysate and incubated. The relative amount of RAB11A-GST 
were examined with immunoblotting. 
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2.10.2 Identifying binding target of G01 with G01 with biotin moiety 
G01 with biotin moiety (B-G01) were added to CaCO-2 cell lysate and 
incubated for 1 h at room temperature. B-G01 bound with protein targets was then 
pulled down by streptavidin beads. The samples were analyzed by silver staining. 
The bands of interest were cut and analyzed by mass spectrometry in Clincal and 
Translational Proteomics Service Center Center for Precision Biomedicine, 
Institute of Molecular Medicine, Houston, Texas. The protein targets were 
confirmed by immunoblotting with their antibodies. 
 
2.11 Enzyme assays 
The relative APEH activity was measured by spectrophotometer. The enzyme 
substrate acetyl-Alanine-p-nitroaniline (Ac-Ala-pNA) was synthesized by Bachem. 
MDCK cells were seeded and treated with other chemical compounds for 48 h. 
Cells were lysed and protein concentrations were determined. The samples each 
containing 250 μg proteins were incubated with DMSO or chemical compounds for 
1h at room temperature. The samples were then heated at 37°C for 2 min before 
1mM ac-Ala-pNA was added. The samples were shaken at 37°C. Absorbance 
under 410nm was measured at different time points.  
 
2.12 Statistical analysis  
Prism (Version 5.0c, GraphPad Software) was used for one-way ANOVA and 







Chapter 3 G01 inhibits RAS PM localization and function 
This chapter is  based upon: Tan L, Cho KJ, Neupane P, Capon RJ, Hancock 
JF: An oxanthroquinone derivative that disrupts RAS plasma membrane 
localization inhibits cancer cell growth. J Biol Chem. 2018 Aug 31;293(35):13696-
13706. The journal does not require permission to reuse publications of the authors 
for dissertation. 
3.1 Introduction 
RAS localization as well as clustering formation on the PM is crucial for the 
downstream signaling [18]. Hence, inhibitors that disrupt cellular distribution or PM 
clustering of RAS are possible to inhibit RAS function. In a high-content screening 
for inhibitors of KRAS binding, a Streptomyces sp. (MST-134270) was isolated and 
used as a source of metabolites. Several new polyketides were isolated, including 
oxanthroquinone. Based on the original structure of oxanthroquinone, a series of 
derivatives were synthesized. These derivatives mislocalized oncogenic KRAS 
with different potencies. The most potent of them was 3-O-methyl oxanthroquinone 
ethyl ester (Figure 1A), hereafter referred to as G01 [97]. We selected G01 for 
further analysis in this study. We investigated whether G01 inhibited the 
localization and cluster of RAS on the PM. We also determined whether G01 






3.2.1 G01 mislocalizes oncogenic KRAS, KRAS4A and HRAS 
from the plasma membrane 
We reported previously the synthesis of a series of oxanthroquinone 
derivatives based on the original microbial polyketide structures identified in a high 
content screen for inhibitors of KRAS PM binding [97]. The most potent synthetic 
compound was 3-O-methyl oxanthroquinone ethyl ester, with a structure as shown 
in Figure 1A, and hereafter referred to as G01 [97]. We selected G01 for further 
analysis. We first examined the RAS isoform specificity of G01. Madin-Darby 
canine kidney (MDCK) cells stably co-expressing mGFP-KRASG12V, or mGFP-
HRASG12V, or mGFP-KRAS4AG12V, and mCherry-CAAX, a general 
endomembrane marker, were treated with different concentrations of G01 for 48h, 
and analyzed by confocal microscopy [102]. The extent of RASG12V 
mislocalization was calculated using manders coefficients, which quantify the 
fraction of mGFP-RASG12V co-localizing with mCherry-CAAX. The greater the 
value of the Manders coefficient, the more extensive is the displacement of mGFP-
RASG12V from the PM [95]. The results show that G01 mislocalizes oncogenic 
KRAS, HRAS, and KRAS4A from the PM with approximately equal potencies, the 




Figure 1. Mislocalization of KRASG12V, HRASG12V, KRAS4A G12V from the 
PM is induced by G01. (A) Structure of G01. (B) MDCK cells stably coexpressing 
mCherry-CAAX, an endomembrane marker, and mGFP-KRASG12V, or mGFP-
HRASG12V, or mGFP-KRAS4A G12V were seeded on coverslips and treated with 
vehicle (DMSO) or G01 for 48 h. Cells were imaged in a confocal microscope. 
Representative images of vehicle (DMSO), 1 μM and 5 μM G01 treatments are 
shown. (C) The extent of RAS mislocalization was quantified with Manders 
coefficients, which evaluate the extent of colocalization of mCherry-CAAX and 
mGFP-RASG12V. Estimated IC50 values for G01 on each cell line were obtained 




3.2.2 G01 impairs spatial organization of RAS on the PM 
In addition to PM subcellular localization, the lateral spatial organization of 
RAS proteins into nanoclusters on the PM is critical for RAS signal transmission 
[103]. To quantify the effect of G01 on RASG12V nanoclustering, intact basal PM 
sheets from MDCK cells expressing mGFP-KRASG12V, mGFP-HRASG12V or 
mGFP-KRAS4AG12V treated with G01 for 48h, were labeled with gold-conjugated 
anti-GFP antibodies and analyzed by electron microscopy (EM). Spatial mapping 
of each RAS protein on the PM revealed significant decreases in the peak values 
of the L(r)–r clustering statistic, Lmax, (Figure 2A), indicating a reduction in the 
amount of nanoclustered KRASG12V, HRASG12V and KRAS4AG12V on the PM.  
We also observed a significant reduction in anti-GFP immunogold labeling of each 
RAS isoform after G01 treatment, again showing that G01 significantly depleted 
KRAS, HRAS and KRAS4A from the inner leaflet of the PM (Figure 2B), 




Figure 2. G01 disrupts the PM nanoscale organization of KRASG12V, 
HRASG12V and KRAS4A G12V. (A) Basal PM sheets were generated from 
MDCK cells stably expressing mGFP-KRASG12V or mGFP-HRASG12V or 
mGFP-KRAS4A G12V treated with vehicle (DMSO) or 1 μM G01 for 24 h and 
imaged by EM after labeling with anti-GFP antibody conjugated to 4.5 nm gold. 
The extent of clustering of the gold particles was analyzed using Ripley’s K-
function expressed as L(r) - r functions and normalized on the 99% confidence 
interval (CI). The maximum value of L(r) – r, defined as Lmax is used as a summary 
statistic. Values of Lmax above the CI indicates nanoclustering, with the extent of 
clustering being reflected by the Lmax value. At least 12 PM sheets were evaluated 
	
	29	
for each condition and RAS isoform. Significant differences from the control pattern 
for G01-treated cells were assessed using bootstrap tests (***, P < 0.001). (B) 
Average mean (± s.e.m. n ≥ 12) gold labeling density on the PM sheets was 
calculated and the statistical significance of differences in gold labeling density 
was evaluated using Student’s t test (**, P < 0.01; ***, P < 0.001).  
 
3.2.3 ERK signaling downstream of oncogenic RAS is abrogated 
by G01 
RAS PM localization and nanocluster formation are critical for signal 
transmission [18]. Thus G01 concentrations that significantly mislocalized 
KRASG12V or HRASG12V or KRAS4A G12V also suppressed ppERK levels in 
MDCK cells stably expressing each oncogenic RAS isoform (Figure 3, A to C). 
Thus oncogenic RAS-MAPK signaling is abrogated by G01. As we did not observe 
significant changes in oncogenic RAS levels, ppERK was not lowered by a 




Figure 3. G01 inhibits oncogenic RAS signaling. MDCK cells stably expressing 
mGFP-KRASG12V (A), or mGFP-HRASG12V (B), or mGFP-KRAS4A G12V (C) 
were treated with vehicle (DMSO) or G01 for 48 h. Levels of ppERK were 
measured by quantitative immunoblotting and normalized to the total level of ERK. 
Representative western blots are shown. The significance of differences between 
mean (± s.e.m. n= 3) drug-treated and control ppERK levels were assessed using 





Figure 4. G01 does not affect RASG12V cellular level. MDCK cells stably 
expressing mGFP-KRASG12V (A), or mGFP-HRASG12V (B), or mGFP-KRAS4A 
G12V (C) were treated with vehicle (DMSO) or G01 for 48 h. Levels of RASG12V 
were measured by quantitative immunoblotting. Representative western blots are 
shown. The significance of differences between mean (± s.e.m. n= 3) drug-treated 




3.2.4 G01 inhibits the proliferation of RAS-less mouse embryonic 
fibroblasts and KRAS-transformed tumor cell lines  
We first tested the effect of G01 on the proliferation of RAS-less mouse 
embryonic fibroblasts (MEFs) expressing KRASG12V or KRASG12D or 
BRAFV600E. These are cell lines generated from KRAS-floxed, NRAS-null and 
HRAS-null mice and express a single transgene that activates the RAS signaling 
pathway [104]. Interestingly, 5 μM G01 treatment for 72 h, significantly inhibited 
proliferation of KRASG12V and KRASG12D RAS-less MEFs, but not BRAFV600E 
RAS-less MEFs (Figure 5A). This result suggests that G01 inhibits cell growth at 
the level of KRAS but not RAF, consistent with an effect on KRAS PM binding. 
Finally, we tested the efficacy of G01 on a panel of 14 pancreatic, lung, endometrial, 
and colon tumor cell lines, which express wild-type or oncogenic mutant KRAS. 
G01 more potently inhibited the proliferation of pancreatic, endometrial, and colon 
tumor cells that expressed oncogenic KRAS (Figure 5B). G01 also inhibited the 
proliferation lung tumor cell lines, but without evidence of increased potency in 




Figure 5. G01 inhibits the proliferation of oncogenic KRAS dependent cell 
lines. (A) RAS-less MEF cells rescued by expressing KRASG12V, or KRASG12D, 
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or BRAFV600E were seeded in 24-well plates and treated with vehicle (DMSO) or 
5 μM G01 for 48 h. The cells were detached and counted. For graphing cell 
numbers were normalized to the respective mean of number of vehicle (DMSO) 
treated cells. The statistical significance of differences in actual cell numbers 
between control and treated cells (± s.e.m. n= 3) were evaluated by Student’s t (**, 
P < 0.01; ***, P < 0.001). (B) A panel of wild-type (WT) or oncogenic mutant (Mut) 
KRAS-expressing tumor cells and treated for 72 h with vehicle (DMSO) or 5 μM 
G01. The cells were detached and counted. For graphing cell numbers were 
normalized to the respective mean of number of vehicle (DMSO) treated cells.  The 
statistical significance of differences in actual cell numbers between control and 
treated cells (± s.e.m. n= 3) were evaluated by Student’s t test (**, P < 0.01; ***, P 
< 0.001). Results with pancreatic, endometrial, lung, and colon tumor cells are 
shown respectively.  
 
3.3 Discussion 
We show here, using fluorescence and electron microscopy that G01 potently 
mislocalizes oncogenic KRAS, HRAS and KRAS4A from the PM to 
endomembranes. G01 also disrupts KRAS, HRAS and KRAS4A nanocluster 
formation. Concordant with previous work showing that RAS PM localization and 
nanocluster formation is crucial for biological function, G01-induced changes to 
RAS cellular localization and PM spatial organization significantly abrogated RAF-
MAPK signaling downstream of oncogenic KRAS, HRAS and KRAS4A. G01 also 
inhibited the proliferation of RAS-less MEF cells expressing oncogenic KRAS but 
not that of RAS-less MEFs expressing oncogenic BRAF, confirming that inhibition 
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was effected at the level of RAS. In cancer cell proliferation assays, G01 more 
potently inhibited the proliferation of pancreatic, colon, endometrial tumor cell line 
that are oncogenic KRAS dependent, but had less activity against the tumor cell 
lines that expressed wild-type KRAS or were KRAS independent. This selectivity 
for KRAS function was not observed in the small set of lung cancer cell lines we 
examined, perhaps indicating that wild type RAS signaling, which would also be 
suppressed by G01, is required to support the transformed phenotype in these 
lung cancer cell lines. Taken together, we conclude that G01 is a novel inhibitor of 











Chapter 4 G01 disrupted SM metabolism as well as RE function 
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localization inhibits cancer cell growth. J Biol Chem. 2018 Aug 31;293(35):13696-
13706. The journal does not require permission to reuse publications of the authors 
for dissertation. 
4.1 Introduction 
Although we have evidence showing that G01 inhibits oncogenic RAS PM 
localization and function, the mechanism of action of G01 for KRAS mislocalization 
was not understood. SM metabolism maintains the PM localization of PtdSer and 
cholesterol, which are critically important for the PM localization and clustering of 
K- and H-RAS [39, 40]. Therefore, we tested whether G01 disrupted SM 
metabolism. In addition, because all RAS isoforms traffic via the RE to the PM [46, 
51], we investigated whether G01 disrupted RE function. Finally, we synthesized 
G01 with a PEG linker and a biotin moiety for identification of the protein target 
that binds to G01.  
 
4.2 Results 
4.2.1 G01 enhances cellular levels of SM and ceramide 
Recent studies have implicated SM metabolism in the maintenance of normal 
PM lipidomic content and organization that are critical for both KRAS and HRAS 
membrane binding and nanoclustering [39, 40]. To determine whether G01 
disrupts SM metabolism, we first measured SM and ceramide (Cer) levels using 
whole cell lipidomics. MDCK cells treated with G01 for 48h exhibited significantly 
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increased SM and Cer levels (Figure 6A). The enhancement in SM level was 
confirmed by staining with mGFP-lysenin that specifically binds SM. MDCK cells 
were treated with G01 for 48h and incubated with mGFP-lysenin with and without 
membrane permeabilization. Images were obtained with a confocal microscope. 
Concordant with the lipidomic analysis, G01 enhanced mGFP-lysenin staining of 
the exofacial leaflet of the PM as well as intracellular membranes (Figure 6, B and 
C). Disrupted SM metabolism may result in mislocalization of PtdSer and 
cholesterol from the PM [96]. MDCK cells stably co-expressing mCherry-CAAX 
and mGFP-LactC2, a probe for PtdSer, were treated with G01 for 48h and 
analyzed by quantitative confocal microscopy. The results show that G01 disrupts 
the PM localization of mGFP-LactC2, and by inference PtdSer, albeit with a 
potency much lower than that against RAS (Figure 6D). Similarly, when MDCK 
cells stably co-expressing mCherry-D4H, a cholesterol probe, were treated with 
G01 for 48h, the mCherry-D4H probe was mislocalized from the PM and 
accumulated in intracellular puncta, but again this effect was only observed with 




Figure 6. SM metabolism is disrupted in G01-treated cells. (A) MDCK cells 
stably expressing mGFP-KRASG12V, or wild-type MDCK cells were grown in the 
presence of vehicle (DMSO) or 5nM STS or 1 μM G01 for 48 h. Whole cell lysates 
were prepared and total SM and Cer levels were measured. The graph shows SM 
and Cer levels relative to control, the significance of differences were assessed in 
one-way ANOVA using the actual mean lipid pmol values (± s.e.m. n=3) (**, P < 
0.01; ***, P < 0.001). (B) Wild-type MDCK cells were treated with G01 for 48 h, 
stained with mGFP-lysenin and imaged in a confocal microscope with fixed 
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imaging parameters to assess comparative fluorescent intensities. The PM mGFP 
fluorescence intensity was quantified using the region of interest tool in ImageJ. 
The values of fluorescence intensity were normalized to the mean of those in 
vehicle (DMSO) treated group (± s.e.m. n ≥ 20)). The statistical significance of 
differences in relative fluorescence intensity was assessed by one-way ANOVA 
(***, P < 0.001). (C) Wild-type MDCK cells were treated with G01 for 48 h and 
permeabilized, stained with GFP-lysenin and 4',6-diamidino-2-phenylindole (DAPI). 
Cells were imaged in a confocal microscope with fixed imaging parameters. 
Representative images were shown. (D) MDCK cells stably coexpressing mGFP-
LactC2 and mCherry-CAAX were treated with G01 for 48 h. Cells were fixed and 
imaged in a confocal microscope. Colocalization between mGFP-LactC2 and 
mCherry-CAAX was quantified by Manders coefficients. The IC50 value was 
estimated from the Manders coefficient (± s.e.m. n= 3) dose-response plot. (E) 
MDCK cells stably coexpressing mGFP-LactC2 and the cholesterol probe, 
mCherry-D4H, were treated with G01 for 48 h. Cells were fixed and imaged in a 
confocal microscope. Representative images are shown.  
 
4.2.2 G01 synergizes with other compounds that disrupt SM 
metabolism  
To explore the potential molecular mechanism of action of G01, we tested for 
synergism between G01 and three other compounds that disrupt SM metabolism: 
fumonisin B1 (FB1), STS and R-fendiline. The premise being compounds that have 
different molecular targets in a common metabolic pathway that is involved in 
maintaining KRAS PM localization may exhibit synergism for KRAS redistribution. 
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FB1 is a Cer synthase inhibitor that decreases cellular SM and Cer levels [96]. 
STS when used at very low concentrations, well below the IC50 for PKC inhibition 
[39, 40], increases the rate of SM synthesis by decreasing the level of ORMDL 
proteins, which negatively regulate the enzyme serine-palmitoyltransferase [96]. 
R-fendiline is an inhibitor of ASM. R-fendiline treatment therefore elevates the SM 
content of the endolysomal system [39, 40]. We treated MDCK cells coexpressing 
mGFP-KRASG12V and mCherry-CAAX with various concentrations of G01, in the 
presence of a fixed low concentration (10μM) of FB1 for 48h and imaged the cells 
using confocal microscopy, Manders coefficients were measured and IC50s were 
calculated. G01 alone mislocalizes KRASG12V with an IC50 of ~1μM, while FB1 
improves the IC50 to ~0.2μM (Figure 7A). To formally quantify synergism, we 
calculated a combination index (CI) using the Chou-Talalay method. By this 
method a CI of 1 indicates an additive effect, a CI < 1 indicates synergism and a 
CI > 1 indicates antagonism [105]. This analysis confirms that G01 synergizes with 
FB1 for KRAS mislocalization over most of the G01 concentration range tested 
(Table 1A). Reciprocally, a low dose of G01 shifted the dose response curve of 
FB1 to the left indicating a reduced IC50 (Figure 7A). Chou-Talalay analysis again 
confirmed synergism over most of the FB1 concentration range tested (Table 1A). 
Similar experiments with G01 and STS, G01 and R-fendiline showed strong 
synergism between each pair of compounds for KRAS mislocalization from the PM 
(Figure 7, B and C; Table 1, B and C). These results strongly suggest that the 
molecular target of G01 impacts SM metabolism but is likely different from the 
enzymes inhibited by FB1, STS and R-fendiline.  
Given that G01 synergizes with compounds that perturb SM metabolism for 
KRASG12V mislocalization, we also tested RAS-RAF-MAPK signaling in MDCK 
	
	41	
cells expressing KRASG12V treated with synergistic drug combinations. 
Concordant with the mislocalization data shown in Figure 7, treatment with 10μM 
FB1 or 0.5μM G01 alone had no effect on pp-ERK levels, whereas the drug 
combination significantly inhibited RAS-RAF-MAPK signaling (Figure 8A). Similar 
results were obtained with low doses of G01 combined with low doses of STS, or 
R-fendiline, that singly had no effect on RAS-RAF-MAPK signaling, but which in 




Figure 7. The cocktails of G01 with other compounds are more potent for PM 
mislocalization of KRAS. (A) MDCK cells stably coexpressing mCherry-CAAX 
and mGFP-KRASG12V were treated with 10 μM FB1 with variable concentrations 
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of G01, or 0.5 μM G01 with variable concentrations of FB1. Cells were fixed and 
imaged in a confocal microscope. The colocalization between mGFP-LactC2 and 
mCherry-CAAX was quantified by Manders coefficients (± s.e.m. n= 3). IC50 values 
were estimated from the Manders coefficient dose-response plots. (B) MDCK cells 
stably coexpressing mCherry-CAAX and mGFP-KRASG12V were treated with 
0.5nM STS with variable concentrations of G01, or 0.5 μM G01 with variable 
concentrations of STS. Manders coefficients (± s.e.m. n= 3) were quantified and 
IC50 values were estimated. (C) MDCK cells stably coexpressing mCherry-CAAX 
and mGFP-KRASG12V were treated with 2.5 μM R-fendiline with variable 
concentrations of G01, or 0.5 μM G01 with variable concentrations of R-fendiline. 


















FB1 (μM) G01 (μM) CI 
10 0.001 9.82 
10 0.005 12.65 
10 0.01 6.64 
10 0.05 12.69 
10 0.1 0.97* 
10 0.5 0.84* 
10 1 0.11* 
10 2.5 0.26* 
*Synergism between two compounds 
B 
STS (nM) G01 (μM) CI 
0.5 0.0001 7.93 
0.5 0.0005 6.51 
0.5 0.001 0.59 
0.5 0.01 0.46* 
0.5 0.5 0.42* 
0.5 0.1 0.31* 
0.5 0.5 0.56* 
0.5 1 0.52* 





G01 (μM) CI 
2.5 0.0001 4.43 
2.5 0.0005 4.49 
2.5 0.001 3.61 
2.5 0.005 0.83* 
2.5 0.01 0.92* 
2.5 0.05 0.35* 
2.5 1 0.19* 
2.5 0.5 0.30* 
*Synergism between two compounds 
G01 
(μM) 
FB1 (μM) CI 
0.5 0.001 11.05 
0.5 0.01 9.31 
0.5 0.05 5.52 
0.5 0.1 10.29 
0.5 0.5 0.95* 
0.5 1 0.73* 
0.5 5 0.38* 
0.5 10 0.69* 
0.5 15 0.24* 
*Synergism between two compounds 
G01 (μM) STS (nM) CI 
0.5 0.001 11.73 
0.5 0.005 8.37 
0.5 0.01 0.96* 
0.5 0.05 0.48* 
0.5 0.1 0.40* 
0.5 0.5 0.57* 
0.5 1 0.71* 
0.5 5 0.23* 







0.5 0.05 13.57 
0.5 0.1 7.28 
0.5 0.5 12.99 
0.5 1 1.39 
0.5 2.5 0.69* 
0.5 5 0.58* 
0.5 10 0.25* 
0.5 12.5 0.35* 
*Synergism between two compounds 
Table 1. G01 synergizes with modulators of SM metabolism for KRAS 
mislocalization. Synergism was quantified by the Chou and Talalay method using 
Compusyn software (Version 1.0; ComboSyn, Inc.). Combination indexes (CI) 
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were calculated using the mean value of Manders coefficients from three 
independent experiments (Synergism, CI <1; additive effect, CI = 1; antagonism, 
CI > 1). 
 
Figure 8. The cocktails of G01 with other compounds are more potent for 
inhibition of oncogenic KRAS signaling. MDCK cells stably expressing mGFP-
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KRASG12V were treated for 48h with vehicle (DMSO), low dose G01 alone, low 
dose FB1 alone, or a combination of low dose FB1 with G01 (A), or staurosporine 
(STS) alone, or a combination of STS with G01 (B), or low dose R-fendiline alone 
or a combination of low dose R-fendiline with G01 (C). Levels of ppERK were 
measured by quantitative immunoblotting and normalized to the total level of ERK. 
Representative western blots are shown. The significance of differences between 
mean (± s.e.m. n= 3) drug-treated and control ppERK levels were assessed using 
one-way ANOVA (*, P < 0.05; **, P < 0.01).  
 
4.2.3 G01 disrupts the endocytic recycling of epidermal growth 
factor receptor and transferrin receptor 
Normal function of the RE is required to maintain KRAS, HRAS, and NRAS 
on the PM [46, 51]. We therefore examined whether G01 compromises the cellular 
distribution of other proteins that recycle through the RE. We first observed the 
localization and trafficking of epidermal growth factor receptor (EGFR) [106-108]. 
Chinese hamster ovary (CHO) cells stably expressing mGFP-EGFR were treated 
with G01 for 48h (or left untreated), serum starved and incubated with EGF on ice 
for 15mins and then imaged by confocal microscopy at intervals following warming 
to 37°C. For control cells with no G01 treatment, mGFP-EGFR was predominantly 
localized to the PM at 0 min and then rapidly endocytosed, such that at 15 min and 
30 min, the majority of mGFP-EGFR was localized to intracellular vesicles, before 
being substantially returned to the PM by 60mins (Figure 9A). In G01 treated cells, 
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a large fraction of mGFP-EGFR was already redistributed from the PM at 0 min, 
and at subsequent time points the remaining PM bound mGFP-EGFR was 
internalized. In striking contrast to control cells at 60 min, mGFP-EGFR was 
concentrated in the perinuclear region (Figure 9A). In parallel experiments, we 
quantified the amount of mGFP-EGFR on the PM during EGF-induced endocytosis 
using anti-GFP immunogold labeling and EM of PM sheets. The results are 
concordant with the confocal imaging and show significantly lower levels of mGFP-
EGFR on the PM in G01-treated cells at 0 min and 60 min (Figure 9B). Together 
these data illustrate that G01 inhibits the endocytic recycling of EGFR, most 
probably, given the perinuclear accumulation of internalized EGFR, by inhibiting 
the exit of EGFR from the RE.  
We next examined endocytic recycling of the transferrin receptor (TfR). Alexa 
Fluor 555 conjugated transferrin (Tf-555) was bound to the surface of MDCK cells 
that had been treated for 48h with G01 or left untreated. Excess Tf-555 was 
removed by washing and the cells immediately imaged. The surface fluorescence 
intensity was much lower in the G01-treated cells, indicating less bound Tf-555 
and thus a lower density of TfR on the PM (Figure 10A). MDCK cells stably 
expressing mGFP-LactC2 were treated with G01 for 48 h, incubated with Tf-555 
on ice then imaged by confocal microscopy at intervals following warming to 37°C. 
PtdSer is not mislocalized by 1μM G01 therefore GFP-LactC2 can be used as a 
PM marker for quantification. In control cells Tf-555 was rapidly internalized and 
substantially returned to the PM by 60mins; as shown in the images in Figure 10B 
that were quantified using Manders coefficients to evaluate the extent of co-
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localization between mGFP-LactC2 and Tf-555. Whereas in G01 treated cells Tf-
555 was rapidly internalized but not returned to the PM (Figure 10, B and C). These 
results together suggest that the endocytic recycling of TfR is inhibited by G01. We 
next conducted similar experiments with Alexa Fluor 647 conjugated cholera toxin 
b subunit (CTB-647), using A431 cells that express the ganglioside GM1, which is 
the surface receptor for cholera toxin [109]. After initial incubation with CTB-647 
we observed no difference in PM fluorescence intensity between G01 treated and 
untreated cells, suggesting that the level of GM1 expressed on the surface of A431 
cells was unchanged by G01 treatment (Figure 10A). To quantify the internalization 
of CTB-647 we stained fixed cells with the impermeable PM marker Alexa Fluor 
488 conjugated to wheat germ agglutinin (WGA-488) that binds N-
acetylglucosamine and N-acetylneuraminic acid. Manders coefficients were then 
used to measure the rate of loss of CTB-647 from the PM. This analysis revealed 
no difference in the kinetics of CTB-647 internalization in A431 cells after G01 
treatment (Figure 11, A and B). We therefore conclude that the internalization of 




Figure 9. EGFR endosomal recycling is inhibited by G01. (A) CHO cells stably 
expressing mGFP-EGFR were treated with vehicle (DMSO) or 1 μM G01 for 48 h. 
Cells were serum-starved for 2 h and incubated with 50ng/ml EGF on ice for 20 
min. Excess EGF was washed away with ice-cold PBS. Cells were then incubated 
with fresh warm medium with vehicle (DMSO), or 1 μM G01 at 37 °C and fixed at 
different time points. Cells were imaged in a confocal microscope. Representative 
images of vehicle (DMSO) and 1 μM G01 were shown. (B) In parallel identical 
experiments PM sheets were generated from the CHO cells under identical 
conditions as in (A), labeled with anti-GFP antibody conjugated to 4.5 nm gold and 
imaged by EM. Mean gold density on the PM sheets was determined. The 
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statistical significance of differences in mean (± s.e.m. n ≥ 12) gold labeling density 




Figure 10. Transferrin receptor endocytic recycling is disrupted by G01. (A) 
Wild-type MDCK or A431 cells were treated with vehicle (DMSO) or 1 μM G01 for 
48 h. MDCK and A431 Cells were incubated with Tf-555 or CTB-647 on ice 
respectively for 20min. Excess Tf-555 or CTB-647 was washed away with ice-cold 
PBS. Cells were fixed and observed under a confocal microscope with fixed 
imaging parameters to assess comparative fluorescent intensities.. 
Representative images were shown. (B) MDCK cells stably expressing mGFP-
LactC2 were treated with vehicle (DMSO) or 1 μM G01 for 48 h. Cells were 
incubated with Tf-555 on ice for 20min. Excess Tf-555 was washed away with ice-
cold PBS. Cells were then incubated with fresh warm medium with vehicle (DMSO) 
or 1 μM G01 at 37 °C and fixed at different time points. Cells were imaged in a 
confocal microscope and representative images of vehicle (DMSO), 1 μM G01 are 
shown. (C) Images were analyzed using Manders coefficients to quantify the 
extent of colocalization of mGFP-LactC2 and Tf-555. The statistical significance of 
differences between mean Manders coefficients (± s.e.m. n= 3) at each time point 




Figure 11. Endocytosis of cholera toxin is unaffected by G01. (A) A431 cells 
were treated with vehicle (DMSO) or 1 μM G01 for 48 h. Cells were incubated with 
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CTB-647 on ice for 20min. Excess CTB-647 was washed away by ice-cold PBS. 
Cells were then incubated with fresh warm medium with vehicle (DMSO) or 1 μM 
G01 at 37 °C and fixed at different time points. Cells were incubated with WGA-
488 for 10min and mounted. Cells were imaged in a confocal microscope and 
representative images of vehicle (DMSO), 1 μM G01 are shown. (B) Images were 
analyzed using Manders coefficients to quantify colocalization of the PM marker, 
WGA-488 and CTB-647. The statistical significance of differences between mean 
Manders coefficients (± s.e.m. n= 3) at each time point was evaluated using 
Student’s t tests.  
 
4.2.4 G01 does not affect RAB11A localization or function 
RAB11 includes three isoforms, RAB11A, RAB11B, and RAB11C, which are 
expressed in different tissues. Previous reports showed that HRAS was recycled 
via RAB11-positive endomembrane compartments, suggesting that HRAS PM 
localization may be mediated by RAB11 [110]. RAB11 is also important for the 
recycling of KRAS. Expression of inactive RAB11 or knockdown of endogenous 
RAB11 reduced KRAS localization on the PM [51]. We propose that HRAS and 
KRAS PM localization is disrupted when G01 alters RAB11 activity.  
First, we determined the role of RAB11 in KRAS PM localization. Because 
RAB11A, but not RAB11B or RAB11C, is expressed in MDCK cells, we employed 
point mutagenesis to generate constitutively active (RAB11A-Q70L) and 
dominantly negative mCherry-RAB11A (RAB11A-S25N) from wild-type mCherry-
Rab11A (RAB11A-WT). mCherry-RAB11A mutants and mGFP-KRASG12V were 
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transfected into MDCK cells. Cells stably expressing both fluorescence-tagged 
proteins were observed by confocal microscopy. KRASG12V appeared 
mislocalized in MDCK cells expressing RAB11A-Q70L or RAB11A-S25N, but not 
in cells expressing RAB11A-WT, indicating that normal RAB11A biological function 
was critical for maintaining KRAS on the PM (Figure 12A). Both activation and 
inactivation of RAB11A reduced the PM localization of KRAS. 
RAB11A is concentrated in the perinuclear area for the biogenesis of the RE, 
indicating that its localization is crucial for RE biogenesis [111]. We next tested 
whether G01 disrupted RAB11A localization. MDCK cells stably expressing 
mGFP-KRASG12V and mCherry-RAB11A mutants were treated with 1 μM G01 
for 48 h and observed by fluorescence microscopy. In control cells, RAB11A was 
concentrated in the perinuclear area (Figure 12B). In G01-treated cells, 
KRASG12V was mislocalized from the PM, but no changes to RAB11A localization 
were observed, suggesting that G01 does not affect RAB11A cellular distribution 
(Figure 12B). 
Next, we tested whether G01 affected RAB11A activated status. We used a 
pull-down assay with a fragment of FIP3, a protein that binds to RAB11-GTP [101]. 
First, we validated the assay by obtaining lysates of MDCK cells stably expressing 
mCherry-RAB11A-WT, mCherry-RAB11A-Q70L, or mCherry-RAB11A-S25N. 
RAB11A-GTP was then pulled down with the FIP3 fragment and analyzed by 
immunoblotting. The ratio of mCherry-RAB11A-GTP in samples of mCherry-
RAB11A-WT, mCherry-RAB11A-Q70L, and mCherry-RAB11A-S25N was 
approximately 1: 4: 0.1, confirming the validity and sensitivity of the assay for 
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measuring RAB11A-GTP cellular levels (Figure 12C). Next, MDCK cells were 
treated with G01 for 48 h and the relative RAB11-GTP level was determined. An 
approximately equal amount of RAB11-GTP was observed irrespective of G01 




Figure 12. The localization or activity of RAB11A is not affected by G01. (A) 
MDCK cells stably expressing mGFP-KRASG12V and mCherry-RAB11A-WT or 
mCherry-RAB11A-Q70L or mCherry-RAB11A-S25N were fixed by 4% PFA and 
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imaged in a confocal microscope. Representative images are shown. (B) MDCK 
cells stably expressing mGFP-KRASG12V and mCherry-RAB11A-WT were 
treated with vehicle (DMSO) or 1 μM G01 for 48 h. Cells were fixed by 4% PFA 
and imaged in a confocal microscope. Representative images are shown. (C) 
MDCK cells stably expressing mGFP-KRASG12V and mCherry-RAB11A-WT or 
mCherry-RAB11A-Q70L or mCherry-RAB11A-S25N were lysed. GTP-loaded 
mCherry-RAB11A was pulled down and its level was measured by quantitative 
immunoblotting. The level of GTP-loaded mCherry-RAB11A was normalized to the 
total level of mCherry-RAB11A. Representative western blots are shown. (D) 
MDCK cells stably expressing mGFP-KRASG12V were treated with vehicle 
(DMSO) or G01 for 48 h. GTP-loaded endogenous RAB11A was pulled down and 
its level was measured by quantitative immunoblotting. The level of GTP-loaded 
RAB11A was normalized to the total level of RAB11A. Representative western 
blots are shown.  
 
4.2.5 G01 binds to and inhibits the enzyme acylpeptide hydrolase 
To determine the protein target of G01, a compound named as B-G01 was 
synthesized, whose structure consists of a biotin and G01 moiety. We incubated 
vehicle (DMSO) or B-G01 with CaCO2 cell lysate. B-G01 along with its bound 
proteins was pulled down by streptavidin-conjugated beads and analyzed by silver 
staining. A band of ~75 kDa was detected in the sample incubated with B-G01 but 
not in the control sample incubated with streptavidin-conjugated beads alone 
(Figure 13A). The silver stained band was excised and identified by mass 
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spectrometry as acylpeptide hydrolase (APEH). Protein identity was then 
confirmed by immunoblotting (Figure 13B).  
APEH, is a prolyl-oligopeptidase which is responsible for catalyzing the 
removal of Nα-acylated amino acids from peptides and has a general role in protein 
degradation [112-115]. APEH is also capable of breaking down oxidized and 
glycated proteins and has been alternately named oxidized protein hydrolase [116, 
117]. To biochemically verify this result we measured the enzymatic activity of 
APEH by analyzing the release of p-nitroaniline (pNA) from a synthetic peptide, 
acetyl-Alanine-p-nitroaniline (ac-Ala-pNA). The released pNA was detected by 
measuring absorbance at 410 nm (A410). At 15, 60, or 120 min, A410 was 
significantly lower in the G01-treated cell lysate than in the control, indicating a 





Figure 13. APEH is bound to and inhibited by G01. (A) The cell lysate of CaCO2 
cells were incubated with streptavidin beads with DMSO or streptavidin beads with 
B-G01. The proteins that bind streptavidin beads and DMSO or B-G01 were 
analyzed by silver staining (n= 3). Representative silver-stained gel is shown. The 
gel area of 75kDa was cut and analyzed by mass spectrometry. (B) The cell lysate 
of CaCO2 cells were incubated with streptavidin beads with DMSO or streptavidin 
beads combined with B-G01. The proteins that bind streptavidin beads and DMSO 
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or B-G01 were analyzed by immunoblotting. (C) Ac-Ala-pNA was incubated with 
the MDCK cell lysate and absorbance was measured under 410 nm. The statistical 
significance of differences between mean absorbance (± s.e.m. n= 3) at each time 
point was evaluated using Student’s t tests (***, P < 0.001). 
 
4.2.6 Inhibition or knockdown of APEH mislocalizes oncogenic 
KRAS and PtdSer from the PM 
To determine whether downregulation of APEH inhibits PM localization of 
KRASG12V, we knocked down APEH with NT shRNA or APEH shRNAs in MDCK 
cells stably expressing mGFP-tagged KRASG12V and mCherry-tagged CAAX, an 
endomembrane marker (Figure 14A). The cells with stable knockdown of APEH 
were imaged in a confocal microscope. In cells transfected with APEH shRNAs, 
we observed a mislocalization of KRASG12V from the PM, whereas KRASG12V 
was predominantly localized on the PM in cells transfected with NT shRNA (Figure 
14B). The mislocalization of mGFP-KRASG12V from the PM was quantified by 
Manders coefficients [95], which evaluate the extent of colocalization between 
mGFP-KRASG12V and mCherry-CAAX. We observed a significant increase in the 
Manders coefficient in APEH-knockdown cells, indicating a significant 
mislocalization of KRASG12V from the PM (Figure 14C). Previous work has 
identified ebelactone A (ebelactone) as a commercially-available APEH inhibitor 
[114, 118]. We therefore treated MDCK cells stably expressing mGFP-KRASG12V 
and mCherry-CAAX with ebelactone. Similar to the observation in APEH-
knockdown cells, mGFP-KRASG12V localization to the PM was inhibited by 
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ebelactone (Figure 14B) with an IC50 of 206 µM (Figure 14C), which is similar to 
the concentration at which ebelactone inhibited APEH and downstream 
proteasomal function in previous studies [114].  
Next, we confirmed that reduced expression of APEH is causative to KRAS 
mislocalization. MDCK cells stably expressing mGFP-KRASG12V and mCherry-
CAAX with or without APEH knockdown were transfected with APEH cDNA, and 
imaged with confocal microscopy. mGFP-KRASG12V was localized 
predominantly on the PM in the cells transfected with NT shRNA and mislocalized 
from the PM in cells transfected with APEH shRNAs (Figure 15, A to C). The PM 
localization of mGFP-KRASG12V was rescued by the restoration of ectopic APEH 
expression using exogenous cDNA (Figure 15, A to C). These observations 
confirmed that the KRAS mislocalization was induced by the knockdown of APEH 
and not by other off-target effects.  
To explore potential molecular mechanisms for how APEH maintains KRAS 
PM localization and organization we investigated whether APEH regulates the PM 
localization of PtdSer and cholesterol, which are in turn critically important for the 
PM localization and clustering of KRAS and HRAS [31]. APEH was knocked down 
in MDCK cells stably expressing mGFP-LactC2 and mCherry-D4H, which are 
probes of PtdSer and cholesterol respectively. The localization of mGFP-LactC2 
and mCherry-D4H was imaged in a confocal microscope. In control cells, the 
majority of mGFP-LactC2 and mCherry-D4H was localized on the PM. However, 
in APEH-knockdown cells, mGFP-LactC2 and mCherry-D4H were redistributed to 
endomembrane, suggesting a disruption of PtdSer and cholesterol localization 
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(Figure 16A). We next tested whether APEH inhibitors have similar effect on the 
localization of PtdSer and cholesterol. MDCK cells stably expressing mGFP-
LactC2 and mCherry-D4H were treated with ebelactone or G01 for 48 h and 
imaged. mGFP-LactC2 and mCherry-D4H were mislocalized in G01- or 




Figure 14. Inhibition or knockdown of APEH redistributes KRASG12V from 
the PM. (A) APEH was knocked down with APEH shRNAs or non-target (NT) 
shRNA in MDCK cells stably expressing mGFP-KRASG12V and mCherry-CAAX. 
Cells were maintained in media containing 5μg/ml puromycin. Level of APEH was 
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measured by immunoblotting. (B) MDCK cells stably expressing mGFP-
KRASG12V and mCherry-CAAX with or without the knockdown of APEH, and 
MDCK cells stably expressing mGFP-KRASG12V and mCherry-CAAX with 48 h 
treatment of vehicle (DMSO) or ebelactone or G01 were imaged in a confocal 
microscope. Representative images were shown. (C) The extent of RAS 
mislocalization was quantified with Manders coefficients. The significance of 
differences (± s.e.m. n= 3) were assessed using one-way ANOVA (**, P < 0.01; 





Figure 15. The mislocalization of KRASG12V induced by APEH knockdown 
is rescued by the expression of exogenous APEH. (A) APEH was knocked 
down with APEH shRNAs or non-target (NT) shRNA in MDCK cells stably 
expressing mGFP-KRASG12V and mCherry-CAAX. Cells were maintained in 
media containing 5μg/ml puromycin. Cells were seeded in 12-well plates and 
transfected with 0ug or 0.25ug APEH cDNA. Cells were imaged in a confocal 
microscope and representative images are shown. (B) APEH level was measured 
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with immunoblotting. (C) Manders coefficients were calculated for representation 
of the extent of RAS mislocalization. The significance of differences (± s.e.m. n= 
3) were assessed using Student’s t tests (***, P < 0.001).   
 
Figure 16. PtdSer and cholesterol are mislocalized from the PM by inhibition 
or knockdown of APEH. (A) APEH was knocked down with APEH shRNAs or 
non-target (NT) shRNA in MDCK cells stably expressing mGFP-LactC2 and 
mCherry-D4H. Cells were grown in media with 5μg/ml puromycin and were 
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observed in a confocal microscope. Representative images are shown. (B) MDCK 
cells stably expressing mGFP-LactC2 and mCherry-D4H were treated with vehicle 
(DMSO) or STS or ebelactone or G01 for 48 h. Cells were imaged and 
representative images are shown. 
 
4.3 Discussion 
Several lines of evidence suggest that the mechanism of action of G01 
involves disruption of RE function. Firstly, we observed mislocalization of 
palmitoylated HRAS and KRAS4A, as well as non-palmitoylated KRAS4B with 
approximately equal potency. This result implicates a common component of their 
respective spatial organizing systems that maintains PM localization after 
posttranslational processing, namely the RE [51]. Secondly, the EGFR and TfR 
were aberrantly distributed in G01 treated cells concordant with abnormal 
endocytic recycling [46, 51, 106-108], this was most evident with the EGFR, which 
accumulated in the RE after G01 treatment in EGF stimulated CHO cells.  
We further show that the molecular target of G01 is the enzyme APEH. G01 
bound to APEH with sufficient avidity to allow affinity purification from cell lysates 
and G01 inhibited the enzymatic activity of APEH in biochemical assays. 
Concordant with the biological effect of G01 [119], shRNA knock down of APEH 
expression resulted in KRAS mislocalization from the PM, which was rescued by 
the restoration of ectopic APEH expression. Together these observations reveal 
that APEH is a novel regulator of KRAS PM localization. Two major cellular 
processes are required for the fidelity of KRAS PM targeting: First, the 
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maintenance of a high concentration of PtdSer on the inner leaflet of the PM, which 
is required because the KRAS membrane anchor exhibits exquisite binding 
specificity for this phospholipid [31, 120]. Second, a functioning spatial 
organization system, which in the case of KRAS requires the RE operating in 
concert with the chaperone PDEd and its regulator ARL2 [40, 46, 51]. We show 
here that both of these components are compromised when APEH expression is 
suppressed. PM inner leaflet PtdSer is reduced, resulting in redistribution of the 
PtdSer probe, LactC2 to endomembrane. In addition, our recent results show that 
there is malfunction of the RE as evidenced by aberrant endosomal recycling of 
the EGFR and TfR. It seems likely that the failure to maintain PM PtdSer content 
in APEH-knockdown cells is at least in part also due to aberrant RE function, since 
lipids as well as proteins must be appropriately sorted and recycled after 
endocytosis. Therefore, the mechanism of action of APEH knockdown for KRAS 
mislocalization involves disruption of RE function, concordant with observations in 
G01-treated cells and impairment of the KRAS spatial organizing system and 
reduced PtdSer content of PM are causative of KRAS mislocalization. These 
results were recapitulated by a previously described, albeit much less potent, 
APEH inhibitor, ebelactone [114, 118], which we show here also mislocalized 
KRAS and reduced the PtdSer content of the inner PM. Concordant with the effects 
on KRAS PM localization, our recent results show that APEH knockdown blocked 
MAPK signaling downstream of oncogenic mutant KRASG12V and inhibited the 
proliferation of KRAS-dependent pancreatic cancer cells. By contrast APEH 
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knockdown had minimal effect on the proliferation of pancreatic cancer cells that 
expressed wild type KRAS. 
Of note, our recent results show that APEH knockdown was less efficacious 
at inhibiting pancreatic cancer cell growth than treatment with G01. Moreover, 
whereas G01 elevates cellular SM levels [119], knockdown of APEH had no such 
effect, suggesting that G01 may have other cellular targets in addition to APEH. 
Consistent with this interpretation of the results biochemical assays indeed showed 
that G01 can inhibit both ASMase and NSMase whereas the activity of these 
enzymes was unaffected in APEH-knockdown cells. Interestingly ebelactone also 
elevated cellular SM levels and inhibited NSMase. Previous work has shown that 
inhibition of SMases is of itself sufficient to impair KRAS PM localization [39, 40, 
96], it therefore seems likely that simultaneous perturbation of SM metabolism and 
RE function via APEH inhibition results in the increased potency of G01 for 
inhibition of KRAS-dependent pancreatic cancer cell proliferation.  
We recently identified multiple enzymes in the SM metabolic pathway whose 
pharmacological inhibition, or in some cases pharmacological activation, 
mislocalize KRAS and PtdSer from the PM. In this context we now show in KRAS 
mislocalization assays that G01 synergizes with three inhibitors of different SM 
metabolic enzymes. We propose therefore that G01 modulates SM metabolism, 
but through a molecular target different from those of FB1, R-fendiline and STS. 
Interestingly this synergy was observed with inhibitors that both up regulate and 
down regulate SM levels, indicating the critical importance of PM SM lipid 
homeostasis in maintaining KRAS function. Most interestingly, the synergistic 
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effects on KRAS mislocalization also extended to synergistic inhibition of 
oncogenic KRAS driven MAPK activation. Together these results strongly suggest 
that G01 may have utility in drug cocktails for future anti-RAS therapies.  
Alpha-acetylation of the amino-terminal amino acid of proteins (Na acetylation) 
is a highly prevalent post-translational modification in eukaryotic cells [121].  The 
function of Na acetylation is not fully understood, but there are examples where 
the modification can regulate protein stability, enzymatic activity and protein-
protein interactions.  Na acetylation is irreversible, unlike amino acid side chain 
acetylation. In eukaryotic cells APEH, a ubiquitously expressed cytosolic enzyme, 
catalyzes removal of the Nα-acetylated amino acid from peptides and therefore 
regulates the overall cellular levels of Na acetylated proteins [114]. APEH is also 
able to hydrolyze oxidized or glycated proteins and has been alternately named as 
oxidized protein hydrolase in older literature [116, 117]. Recent studies have 
shown that knockdown or inhibition of APEH blocks the chymotrypsin-like activity 
of the proteasome [114, 122, 123]. Thus, APEH has been advocated to operate as 
a regulator of proteasome that degrades of poly-ubiquitinated and/or oxidized 
proteins. Separately, APEH has also been identified as a component of an enzyme 
complex that repairs DNA single-strand breaks and concordantly was shown to 
translocate into the cell nucleus in response to DNA damage [115].  
Linking these disparate activities of APEH to the perturbation of RE function 
and consequent mislocalization of KRAS that we have described is not 
immediately straightforward.  Taken together, the previous studies broadly suggest 
that APEH is a regulator of cellular protein quality control, given its peptidase 
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activity and role in proteasomal regulation. We therefore speculate that aberrant 
protein quality control causes damage to the endolysosome, which is in turn critical 
for the recycling of RAS and PM lipids [39, 40]. This may be a consequence of 
oxidative stress induced by accumulation of oxidatively damaged proteins [124, 
125], that in turn causes oxidative damage to the endolysosome  and / or 
dysregulation of specific proteins involved in regulating of RE function [126-128]. 
Identifying the precise molecular target(s) may prove elusive, but in support of the 
general mechanism that aberrant protein quality control is involved we show that 
treatment of cells with the proteasome inhibitor, bortezomib phenocopies the effect 
of G01 on KRAS mislocalization. 
Finally, it is interesting to note that APEH is expressed at higher levels in 
cancers expressing oncogenic mutant KRAS than in cancers expressing wild type 
KRAS. This correlation, when taken in the context of our observations that APEH 
activity is required to maintain KRAS and PtdSer on the inner leaflet of the PM, 
highlights the potential utility of APEH inhibitors and perhaps proteasomal 









Chapter 5 Addition of a farnesyl or geranyl moiety potentiates the 
inhibitory effect of G01 on plasma membrane localization as well 
as biological function of oncogenic KRAS 
5.1 Introduction 
To enhance the effect of G01 on oncogenic KRAS PM mislocalization, a 
series of oxanthroquinone derivatives were synthesized based on the original 
structure of G01. The addition of a geranyl or farnesyl moiety to proteins usually 
augments their hydrophobicity, facilitating their attachment to the cell membrane. 
Accordingly, we hypothesized that addition of a geranyl (D01) or farnesyl (D02) 
moiety to G01 could increase its attachment to cell membranes and absorption, 
ultimately potentiating KRAS mislocalization. In addition, given the synergistic 
action of STS, FB1, or R-fendiline with G01, we speculated that a chimera of STS 
and G01 was more effective at mislocalizing KRAS than G01 alone. Based on this 
assumption, we attached G01 to an STS moiety (D04). During the synthesis of 
D01, D02, and D04, a series of intermediate chemical products were generated. 
As they all shared the G01 backbone, we tested their ability to mislocalize 
oncogenic KRAS from the PM as well. 
 
5.2 Results 
5.2.1 D01 or D02 is more potent than G01 at mislocalizing 
oncogenic KRAS 
MDCK cells stably co-expressing mGFP-KRASG12V and mCherry-CAAX 
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were treated with oxanthroquinone derivatives for 48 h. We show that C10 or C11 
or C12 mislocalized KRAS from the PM with IC50 ~1 μM, while H09 or D04 did not 
mislocalize KRAS (Figure 17 and 18). Interestingly, D01 or D02 mislocalized KRAS 
with IC50 ~0.006 μM or ~0.06 μM, respectively (Figure 19). Therefore, we conclude 





Figure 17. KRASG12V is mislocalized by C10 or C11 but not by H09. (A) 
Structure of H09, C10, and C11. (B) MDCK cells stably expressing mGFP-
KRASG12V and mCherry-CAAX were treated with vehicle (DMSO) or H09 or C10 
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or C11 for 48 h and imaged in a confocal microscope. Representative images are 
shown. (C) The extent of RAS mislocalization was quantified with Manders 
coefficients. Estimated IC50 values were obtained from the Manders coefficient (± 
s.e.m. n= 3) dose-response plots.  
 
Figure 18. KRASG12V is mislocalized by C12 but not by D04. (A) Structure of 
C12 and D04. (B) MDCK cells stably expressing mGFP-KRASG12V and mCherry-
CAAX were treated with vehicle (DMSO) or C12 or D04 for 48 h and imaged in a 
confocal microscope. Representative images are shown. (C) The extent of RAS 
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mislocalization was quantified with Manders coefficients. Estimated IC50 values 
were obtained from the Manders coefficient (± s.e.m. n= 3) dose-response plots.  
 
Figure 19. KRASG12V is mislocalized by D01 or D02. (A) Structure of D01 and 
D02. (B) MDCK cells stably expressing mGFP-KRASG12V and mCherry-CAAX 
were treated with vehicle (DMSO) or D01 or D02 for 48 h and imaged in a confocal 
microscope. Representative images are shown. (C) The extent of RAS 
mislocalization was quantified with Manders coefficients. Estimated IC50 values 
were obtained from the Manders coefficient (± s.e.m. n= 3) dose-response plots. 
 




We next tested whether D01 or D02 disrupted KRAS nanocluster formation. 
We treated MDCK cells stably expressing mGFP-KRASG12V with 0.01 μM D01 
or 0.1 μM D02. Intact PM sheets were prepared and incubated with anti-GFP 
antibodies conjugated with 4.5-nm gold particles. EM images were analyzed by 
Ripley’s K-function. A significant decrease in the Lmax value was observed in D01- 
or D02-treated cells, indicating significant disruption of KRAS nanoclusters (Figure 
20A). This was accompanied by a significant decrease in the number of gold 
particles and confirmed with results showing that 0.01 μM D01 and 0.1 μM D02 




Figure 20. D01 or D02 disrupts the PM nanoscale organization of KRASG12V. 
(A) MDCK cells stably expressing mGFP-KRASG12V were treated with vehicle 
(DMSO) or 0.01 μM D01 or 0.1 μM D02 for 24 h. Basal PM sheets were generated 
from the drug-treated cells and imaged by EM after labeling with anti-GFP antibody 
conjugated to 4.5 nm gold. The extent of clustering of the gold particles was 
analyzed using Ripley’s K-function. Values of Lmax above the CI indicates 
nanoclustering. Lmax value represents the extent of nanoclustering. At least 12 PM 
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sheets were evaluated for each condition. Significant differences from the control 
pattern for D01- or D02-treated cells were assessed using bootstrap tests (**, P < 
0.01). (B) Average mean (± s.e.m. n ≥ 12) gold labeling density on the PM sheets 
was calculated and the statistical significance of differences in gold labeling density 
was evaluated using one-way ANOVA (*, P < 0.05).  
 
5.2.3 D01 or D02 inhibits MAPK signaling downstream of 
oncogenic KRAS 
To assess whether D01 or D02 was more effective than G01 at inhibiting 
oncogenic KRAS signaling, we measured ppERK in MDCK cells stably expressing 
KRASG12V with D01 or D02 treatment. Treatment with 0.01 μM D01 or 0.1 μM 
D02 significantly reduced ppERK levels without affecting oncogenic KRAS levels, 
indicating significant inhibition of MAPK signaling downstream of oncogenic KRAS 
(Figure 21 and 22). Notably, the same concentrations of G01 did not have any 
effect on ppERK level (Figure 21). These observations confirm that D01 and D02 




Figure 21. Oncogenic KRAS signaling is more potently inhibited by D01 or 
D02. MDCK cells stably expressing mGFP-KRASG12V were treated with vehicle 
(DMSO) or D01 or D02 or G01 for 48 h. ppERK levels were measured by 
quantitative immunoblotting. The relative ppERK level was obtained by 
normalizing ppERK level to pan-ERK level. Statistical significance of differences 




Figure 22. Oncogenic KRAS level is not affected by D01 or D02. MDCK cells 
stably expressing mGFP-KRASG12V were treated with vehicle (DMSO) or D01 or 
D02 for 48 h. KRASG12V levels were measured by quantitative immunoblotting. 
The relative KRASG12V level was obtained by normalizing KRASG12V level to β-
actin level. Statistical significance of differences was evaluated using one-way 
ANOVA. 
 
5.2.4 D01 or D02 selectively inhibits the proliferation of oncogenic 
KRAS-dependent cell lines 
We next tested whether D01 or D02 inhibited the proliferation of RAS-less 
MEFs expressing oncogenic KRAS or BRAF. Treatment with D01 or D02 inhibited 
the proliferation of KRASG12V-expressing RAS-less MEFs, but not those 
expressing BRAFV600E (Figure 23A).  
Finally, we tested whether D01 or D02 inhibited the proliferation of oncogenic 
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KRAS-dependent MiaPaCa-2 pancreatic tumor cell lines. The latter were 
compared to BxPC3 cells, which express wild-type KRAS and are therefore KRAS-
independent. The two cell lines were treated with D01 or D02 for 72 h. We report 
that proliferation of BxPC3 cells was not affected, whereas that of MiaPaCa-2 cells 
were significantly inhibited, indicating that D01 or D02 selectively inhibited the 




Figure 23. The proliferation of KRAS-dependent cell lines is selectively 
inhibited by D01 or D02. RAS-less MEF cells rescued by expressing KRASG12V 
or BRAFV600E (A), and pancreatic cancer cells (B) were seeded in 24-well plates 
and treated with vehicle (DMSO) or D01 or D02 for 72 h. Cells were detached and 
counted. Relative cell numbers were obtained by normalizing numbers of drug-
treated cells to DMSO-treated cells. Statistical significance of differences was 
evaluated using one-way ANOVA (**, P < 0.01; ***, P < 0.001). 
 
5.2.5 D01 did not affect SMase activity 
We have reported in the previous chapter that G01 enhanced cellular SM 
levels, which contributed to G01-induced KRAS mislocalization from the PM [119]. 
Our recent finding shows that G01 inhibited acid SMase (ASMase) and neutral 
SMase (NSMase), which are responsible for catalyzing the breakdown of SM. To 
test whether D01 also affects SMase function, we tested SMase enzymatic activity 
in D01-treated MDCK cells. We show that D01 did not affect SMase activity in both 
neutral and acidic pH environments, suggesting no inhibitory activity towards 




Figure 24. SMase function is not affected by D01. MDCK cells were treated with 
vehicle (DMSO) or GW4869 or G01 or D01 or fendiline for 48 h and lysed. Cell 
lysates were analyzed for neutral and acid SMase activity. The significance of 
differences was determined using one-way ANOVA (***, P < 0.001).   
5.3 Discussion 
We show that addition of a geranyl or farnesyl moiety to G01, resulting in D01 
or D02, respectively, further inhibits oncogenic KRAS PM localization and signaling. 
The observed increased potency for KRAS mislocalization indicates enhanced 
intake of these compounds by the cells, which is consistent with previous studies 
showing that farnesyl or geranyl groups improved proteins’ hydrophobicity [129]. 
Our recent experiments show that G01 treatment is more efficacious at 
inhibiting pancreatic cancer cell proliferation than APEH knockdown. This is 
because G01 not only inhibits APEH function, but perturbs SM metabolism as well. 
The simultaneous disruption of APEH function and SM metabolism may be 
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causative to the enhanced potency of G01 for inhibiting the proliferation of KRAS-
dependent cancer cells. In this chapter, we show that D01 did not cause inhibition 
of cellular SMase function. This may be the reason why D01 is not very efficacious 
at inhibiting the proliferation of KRAS-dependent pancreatic cancer cells, even at 
a concentration that is much higher than that for mislocalizing KRAS. 
Besides prenylation, fatty-acetyl modification such as N-myristoylation and 
palmitoylation, also contribute to proteins’ hydrophobicity and membrane binding 
capacity. Therefore, the addition of N-myristoyl or palmitoyl groups to 
pharmacological agents may represent a promising avenue for enhancing the 












Chapter 6 Discussion and future directions 
In this study, we identified G01 as a potential anti-RAS therapeutic. G01 
mislocalized KRAS, HRAS, and KRAS4A from the PM and disrupted the 
nanoclusters of RAS proteins remaining on the PM. Previous studies indicated that 
RAS must localize on the PM and assemble into nanoclusters to recruit 
downstream effectors [18, 31]. Concordant with these studies, MAPK signaling 
downstream of RAS was disrupted by G01-induced PM mislocalization of RAS.  
We further identified the molecular target of G01 to be APEH. G01 bound to 
APEH and inhibited the enzymatic activity of APEH. Concordant with the biological 
effect of G01, APEH knockdown or inhibitors mislocalized KRAS from the PM, 
inhibited the nanoclusters of KRAS remaining on the PM, and abrogated the MAPK 
signaling downstream of KRAS.  
KRAS PM targeting requires two major cellular processes. First, a high 
concentration of PtdSer is required to be maintained on the inner leaflet of the PM, 
because KRAS binds specifically to PtdSer [31, 120]. Second, a functioning spatial 
organization system, which involves the RE operating in concert with PDEd and 
ARL2, is needed [40, 46, 51]. In this study, we show that both of these two cellular 
processes are compromised in APEH-knockdown or -inhibited cells. It seems likely 
that the mislocalization of PtdSer is at least partially induced by the aberrancy of 
RE function because lipids must be properly sorted and recycled after endocytosis. 
Concordant with the effect on KRAS PM localization, APEH knockdown or 
inhibition selectively blocked the proliferation of oncogenic KRAS-dependent 
cancer cells, but have minimal effect on the proliferation of cancer cells expressing 
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wild-type KRAS. Interestingly, G01 inhibited the proliferation of KRAS-dependent 
cancer cells more potently than APEH knockdown. Moreover, G01 increased 
cellular SM level and inhibited SMase function [119], which was not observed in 
APEH-knockdown cells. These observations suggest that G01 have other cellular 
targets in addition to APEH. Recently we have reported that inhibition of SMases 
is of itself sufficient to impair KRAS PM localization [39, 40, 96]. Therefore, the 
simultaneous perturbation of SM metabolism and RE function via APEH inhibition 
is likely to result in the increased potency of G01 for inhibition of KRAS-dependent 
pancreatic cancer cell proliferation.  
In our recent studies, several inhibitors of enzymes in the SM metabolism 
have been identified [39]. This study further shows that G01 synergized with three 
of these inhibitors, which target different SM metabolic enzymes, for mislocalizing 
KRAS and inhibiting MAPK signaling pathway. We therefore propose that G01 
modulates SM metabolism through a molecular target different from those of FB1, 
R-fendiline, and STS, and that G01 may be used in drug cocktails for future anti-
RAS therapies. 
Previous studies suggest that APEH regulates cellular protein quality control, 
due to its peptidase activity and its role in the proteasomal regulation [114]. APEH 
and proteasome are responsible for the removal of oxidized proteins in cells [116, 
117]. Therefore, we speculate that the aberrant protein quality control causes 
damage to the endolysosome, which is crucial for the recycling of RAS and PM 
lipids (Figure 25) [39, 40]. This may be a consequence of oxidative stress induced 
by accumulation of oxidatively damaged proteins [124, 125], that in turn causes 
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oxidative damage to the endolysosome and/or dysregulation of specific proteins 
involved in regulating of RE function (Figure 25) [126-128]. This speculation is 
further supported by our recent observation of KRAS PM mislocalization in cells 
treated with proteasome inhibitor, bortezomib. 
APEH is more expressed in cancers expressing oncogenic mutant KRAS than 
in cancers expressing wild type KRAS. This correlation, when taken in the context 
of our observations that APEH activity is required to maintain KRAS and PtdSer 
on the inner leaflet of the PM, highlights the potential utility of APEH inhibitors and 
perhaps proteasomal inhibitors in the treatment of KRAS-dependent pancreatic 
cancer. Therefore, the future direction of this study is to test APEH inhibitors, such 
as ebelactone and G01, and perhaps proteasome inhibitors for inhibition of 
oncogenic KRAS-dependent xenograft tumors in mice. Due to our observation of 
the synergism effect between G01 and other compounds, we will also test drug 
cocktails in vivo. Besides G01, we have developed D01 and D02, which are more 
potent than G01 for mislocalizing KRAS from the PM. We will test them in 
combination with other pharmacological agents for inhibition of oncogenic KRAS-







Figure 25. Molecular machineries involved in maintaining RAS PM 
localization targeted by G01. APEH inhibition by G01 and the subsequent 
proteasome inhibition impair cellular protein degradation. Thus, cellular protein 
quality control is compromised. The abberant protein quality control causes 
damage to the endolysosome, which is critical for the RE-mediated endosomal 
recycling of RAS and PM lipids. Besides APEH, SMase activity is inhibited by G01 
as well. Because SMases are responsible for breaking down SM to ceramide, the 
inhibition of SMases by G01 increases cellular SM level and causes aberrant 
endolysosomal function, perturbing the endosomal recycling of KRAS and PM 
lipids. Besides G01, a disruption of KRAS and PM lipids was also observed in cells 
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